ストックスクリーナーアプリを入手
38.77
0.44%
-0.17
アフターアワーズ：
38.77
前日終値:
$38.94
開ける：
$38.86
24時間の取引高:
261.54K
Relative Volume:
0.33
時価総額：
$1.45B
収益：
$272.30M
当期純損益:
$-5.14M
株価収益率:
-237.13
EPS:
-0.1635
ネットキャッシュフロー:
$42.76M
1週間 パフォーマンス:
+0.83%
1か月 パフォーマンス:
-8.71%
6か月 パフォーマンス:
-5.30%
1年 パフォーマンス:
+22.07%
1日の値動き範囲:
$37.18
$39.01
1週間の範囲:
$36.25
$39.93
52週間の値動き範囲:
$28.54
$54.85
Harrow Inc Stock (HROW) Company Profile
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
38.77 | 1.40B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 開始されました | BTIG Research | Buy |
| 2025-06-10 | 開始されました | William Blair | Outperform |
| 2025-02-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-12-04 | 繰り返されました | B. Riley Securities | Buy |
| 2024-04-11 | 開始されました | Craig Hallum | Buy |
| 2022-09-08 | 再開されました | B. Riley Securities | Buy |
| 2021-10-14 | 再開されました | B. Riley Securities | Buy |
| 2021-09-24 | 開始されました | Aegis Capital | Buy |
| 2021-07-02 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Harrow Inc (HROW) 最新ニュース
Harrow Inc (HROW) Institutional Confidence - TradingKey
Harrow Inc (HROW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harrow Schedules Aug. 11 Call to Discuss Second-Quarter Results - Stock Titan
Harrow Inc (HROW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harrow, Inc. Revenue Breakdown – NASDAQ:HROW - TradingView
Harrow Inc (HROW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harrow Inc (HROW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Harrow Inc (HROW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harrow Inc (HROW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
HROW|Harrow Inc|Price:39.409|Chg%:+0.959 - TradingKey
Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis - TradingKey
HROW|Harrow Inc|Price:37.470|Chg%:-0.980 - TradingKey
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo
HROW Reiterated by BTIG -- Price Target Maintained at $63.00 - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
Harrow Inc (HROW) Shares Fall 4.7% -- What GF Score of 80 Tells Investors - GuruFocus
Samsung Bioepis, Harrow present SB11 biosimilar study results By Investing.com - Investing.com South Africa
Harrow (HROW) Unveils Positive Interim Data on SB11 at Retina Sp - GuruFocus
Samsung Bioepis, Harrow present SB11 biosimilar study results - Investing.com India
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 - The Manila Times
Samsung Bioepis and Harrow Present Interim Data from a - GlobeNewswire
Harrow presents studies on eye care products at medical meeting By Investing.com - Investing.com Nigeria
Harrow Announces ASRS 2026 Presentation of Studies Supporting IHEEZO and BYOOVIZ in Retina Care - Quiver Quantitative
Harrow presents new clinical data supporting IH... - Pluang
Harrow presents studies on eye care products at medical meeting - Investing.com
Nearly 20,000 Injections: IHEEZO Finds No Evidence of Added Endophthalmitis Risk - Stock Titan
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting - GlobeNewswire
Harrow Health stock trades steady as recent earnings and product expansion frame the outlook - AD HOC NEWS
Harrow Inc. Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock RisesPre-Earnings Drift - dars.gov.et
Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 80 Tells Investors - GuruFocus
Harrow Among 3 Prime Growth Stocks With Significant Insider Ownership - simplywall.st
Harrow stock rises on recent results and market value - Ad-hoc-news.de
HROW6348836 Bond Profile — Key Metrics - TradingView
HROW6348836 Bond Coupon Profile — Rate & Payments - TradingView
Harrow Inc (HROW) Shares Surge 3.9% -- What GF Score of 81 Tells Investors - GuruFocus
Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW) - Seeking Alpha
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating, Announces Target Price $59 - Moomoo
Harrow Inc. (HROW) Slips 1% But Holds Key Support Above $40Dividend Growth Stocks - DonanımHaber
Analysts Are Optimistic We'll See A Profit From Harrow, Inc. (NASDAQ:HROW) - 富途牛牛
HROW Q1 2026 Earnings: EPS Misses Estimates Sharply Amid Operational ChallengesQuarterly Earnings - dars.gov.et
HROW News | HARROW INC (NASDAQ:HROW) - ChartMill
Harrow relaunches biosimilar Byooviz in the US - Eyes On Eyecare
Harrow Announces Commercial Launch of BYOOVIZ® in the United States - Sahm
Enterprise value to EBITDA forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to book forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to earnings forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Price to sales forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to EBIT forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Enterprise value to revenue forward of Harrow, Inc. – NASDAQ:HROW - TradingView
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow Inc (HROW) 財務データ
収益
当期純利益
現金流量
EPS
Harrow Inc (HROW) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SILVERNAIL LAUREN P | Director |
May 18 '26 |
Buy |
31.00 |
1,000 |
31,000 |
1,000 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
May 14 '26 |
Buy |
30.20 |
10,000 |
302,000 |
2,996,130 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
May 14 '26 |
Buy |
29.90 |
3,500 |
104,650 |
814,679 |
| Opaleye Management Inc. | 10% Owner |
Mar 04 '26 |
Sale |
39.67 |
138,263 |
5,485,184 |
59,428 |
| Opaleye Management Inc. | 10% Owner |
Mar 03 '26 |
Sale |
39.15 |
60,309 |
2,361,242 |
63,691 |
| Opaleye Management Inc. | 10% Owner |
Feb 27 '26 |
Sale |
54.18 |
5,000 |
270,900 |
65,000 |
| Opaleye Management Inc. | 10% Owner |
Jan 06 '26 |
Sale |
53.35 |
20,000 |
1,066,914 |
70,000 |
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
2.08%
0.17%
大文字化:
|
ボリューム (24 時間):